Madanagopalan VG, et al. - In patients treated with intravitreal bevacizumab (IVB; Avastin, Genentech, Inc) for macular edema (ME) secondary to central retinal vein occlusion (CRVO), researchers assessed the impact of baseline biochemical parameters on the improvement in best corrected visual acuity (BCVA) and decrease in central foveal thickness (CFT). For this retrospective study, they examined 70 eyes of 70 candidates with CRVO who had IVB for ME and had at least one month of follow-up after the last injection. Findings revealed that there was a statistically significant reduction in mean CFT after IVB. According to findings, normal baseline renal parameters (BU and SC) predict better visual outcome in CRVO after ME treatment and offer additional benefit above and beyond that obtained with ME reduction. Other parameters such as FBS, PPBS, hemoglobin, glycosylated hemoglobin, and serum lipids have not been linked to BCVA improvement and CFT reduction.